# A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients

> **NCT00002195** · PHASE3 · COMPLETED · sponsor: **Glaxo Wellcome** · enrollment: 290 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Amprenavir
- **DRUG:** Lamivudine
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT00002195
- **Lead sponsor:** Glaxo Wellcome
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 290 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002195, "A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*